NCT04311034已完成1 期
A Phase Ib Study to Evaluate the Efficacy and Safety of RC48-ADC for Injection in Subjects With Advanced Non-small Cell Lung Cancer With HER2 Overexpression or HER2 Mutation
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- Objective Response Rate （ORR）
研究概览
简要总结
This study will evaluate the efficacy and safety of RC48-ADC for injection in subjects with advanced non-small cell lung cancer with HER2 overexpression or HER2 mutation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary signed informed consent.
- •Male or female, Aged between 18 to 75 years.
- •Predicted survival ≥ 12 weeks.
- •According to UICC/AJCC 8th Edition, histologically and/or cytologically-confirmed, cannot be surgically removed, locally advanced or metastatic NSCLC.
- •Locally advanced or metastatic disease had failed at least one systemic treatment.
- •Based on imaging judgment (RECIST 1.1) or clinical status, tumor progression during or after the last treatment before enrollment.
- •HER2 protein overexpression (IHC 2+ or 3 +) or HER2 gene mutation (defined as exon 20 mutation), the previous test results confirmed by the researchers, both research centers and major research centers can be acceptable.
- •The researchers confirmed that the EGFR gene mutation status was negative or positive. For EGFR gene mutation-positive patients, one of the following is met: 1) T790M gene mutation negative, c-Met gene amplification negative and HER2 IHC 2+ or 3+ after first-generation EGFR-TKI drug resistance; 2) Third-generation EGFR-TKI treatment failed and HER2 IHC 2+ or 3+.
- •Measurable lesion according to the RECIST 1.
- •ECOG performance status score of 0 or
- •Adequate organ function: LVEF ≥ 50 %. Hemoglobin ≥ 9g/dL; ANC ≥ 1.5×10^9 /L; Platelets ≥ 100×10^9 /L; Total bilirubin ≤ 1.5×ULN; ALT, AST and ALP ≤ 2.5×ULN and ≤ 5 x ULN with hepatic metastasis; Serum creatinine ≤1.5×ULN, or CrCl ≥ 60mL/min; INR≤ 1.5× ULN, APTT≤ 1.5× ULN.
- •For female subjects: should be surgically sterilized, postmenopausal, or agree to use a medically approved contraceptive (such as an intrauterine device, contraceptives, or condoms) during study treatment and within 6 months after the end of study, the blood pregnancy test within 7 days of study enrollment must be negative and must be non-lactating. Male subjects: Patients who should be surgically sterilized or agree to use a medically approved contraceptive during the study treatment period and within 6 months after the end of the study.
- •Willing and able to follow trial and follow-up procedures.
排除标准
- •Have used T-DM1 or participated in other HER2-ADC clinical studies.
- •Received anti-tumor treatment 4 weeks before study administration, including chemotherapy (late toxicity chemotherapy was 6 weeks before study administration), radiotherapy (palliative local radiotherapy for bone metastases was 2 weeks before the study administration), biological therapy (small molecule targeted drugs were 8 days before the study administration) or immunotherapy, etc.
- •Major surgery was performed within 4 weeks prior to study administration and did not fully recover.
- •Other clinical trial drugs have been used within 4 weeks before the start of study administration.
- •Live vaccine received within 4 weeks before the start of study administration.
- •Have received anti-tumor Chinese medicine treatment within 2 weeks before the start of study administration.
- •History of other malignant tumors within 5 years before signing the informed consent (except for non-melanoma skin cancer, cervical carcinoma in situ that has been effectively treated, or malignant tumors that have been resolved for more than 3 years after effective treatment and are considered to be cured) .
- •Toxicity of previous anti-tumor treatment has not recovered to CTCAE (version 4.03) 0-1, except for the following conditions: a. Hair loss; b. Pigmentation; c. Long-term toxicity caused by radiotherapy, which cannot be restored by the judgement of the investigator.
- •Active central nervous system (CNS) metastasis and/or cancerous meningitis (subjects who have received brain metastasis treatment can participate in this study, provided that the condition is stable (no evidence of progression confirmed by imaging studies at least 4 weeks before study dosing, and all neurological symptoms have returned to baseline levels), no evidence of new or enlarged brain metastases, and discontinuation of steroid treatment at least 7 days before the first dose of trial treatment. This exception does not include cancerous meningitis, which should be excluded whether clinical status was stable).
- •Diagnosed with HBsAg positive and HBV DNA positive, or HCV Ab positive, or HIV Ab positive.
- •Severe arterial/venous thrombosis or cardio-cerebral vascular accidents occurred within 1 year before the study, such as deep vein thrombosis, pulmonary embolism, cerebral infarction, cerebral hemorrhage, myocardial infarction, etc.
- •Active infections requiring systemic treatment.
- •Other lung diseases required systemic treatment such as active tuberculosis, interstitial lung disease, etc.
- •Uncontrolled systemic diseases such as diabetes, hypertension, cirrhosis, etc.
- •Heart failure graded 3 or above by the NYHA.
- •Pleural effusion, pericardial effusion, or peritoneal effusion with clinical symptoms that cannot be controlled by drainage or other methods.
- •Mental illness or substance abuse known to have an impact on compliance with study requirements.
- •Hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs.
- •Any other disease, metabolic abnormality, abnormal physical examination or abnormal laboratory test, etc., based on the judgment of the investigator, it is reasonable to suspect that the patient has a certain disease or condition unsuitable for the research drug, or will affect the interpretation of the research results, or putting patients at high risk.
- •Pregnant or lactating female or female / male who are planning to have children.
- •Insufficient adherence to participate in this clinical study.
- •Any other condition in which the investigator considers the patient unsuitable for this study.
研究组 & 干预措施
RC48
Experimental
干预措施: RC48 (Drug)
结局指标
主要结局
Objective Response Rate （ORR）
时间窗: 15 months
Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR).
Disease Control Rate (DCR)
时间窗: 15 months
Disease Control Rate (DCR) was defined as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents.
Progression Free Survival (PFS)
时间窗: 15 months
Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Duration of Response (DOR)
时间窗: 15 months
Duration of response is the length of time that a tumor continues to respond to treatment without the cancer growing or spreading.
Overall Survival (OS)
时间窗: 24 months
Overall survival, or OS, measures how long patients, who undergo a certain treatment regimen.
次要结局
- Adverse events (AEs)(Up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of RC48-ADC in Subjects With Advanced Breast CancerAdvanced Breast CancerNCT03052634RemeGen Co., Ltd.112
招募中
2 期
A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological MalignanciesGynecological MalignancyNCT04965519RemeGen Co., Ltd.120
已完成
1 期
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid TumorsSolid TumorsNCT02881138RemeGen Co., Ltd.24
已完成
1 期
A Study of RC108-ADC in Subjects With Advanced Malignant Solid TumorsSolid TumorNCT04617314RemeGen Co., Ltd.67
尚未招募
2 期
RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder CancerNon-muscle Invasive Bladder CancerNCT05996952West China Hospital77